|
|
Levy, Rene H. - Professor
Recent Publications:
-
Yao C, Kunze KL,
Kharasch ED, Wang Y, Trager WF, Ragueneau-Majlessi I, Levy RH. Fluvoxamine-theophylline
interaction: gap between in vitro and in vivo inhibition constants toward
cytochrome P4501A2. Clinical Pharmacology & Therapeutics
2001;70:415-424.
- Carlson SP, Ragueneau-Majlessi I, Levy RH. Development of a metabolic drug interaction database at the
University of Washington. In: Rodrigues, AD, ed. Drug-Drug Interactions.
New York: Marcel Dekker, Inc., 2001.
-
Hachad H, Ragueneau-Majlessi
I, Levy RH. New antiepileptic drugs: review on drug interactions. Therapeutic
Drug Monitor 2002;24:91-103.
- Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M. Topiramate and phenytoin pharmacokinetics during repetitive montherapy and combination therapy to epileptic patients. Epilepsia 2002;43:691-696.
- Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91:1923-1935.
- Ragueneau-Majlessi I, Levy RH, and Janik F. Levetiracetam does not alter the pharmacokinetics of oral contraceptive in healthy women. Epilepsia 2002;43:697-702.
- Lakehal F, Wurden CJ, Kalhorn TF, and Levy RH. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.
Epilepsy Res 2002; 52:79-83.
- Chawla J, Le Guern M-E, Alquier C, Kalhorm T, and Levy RH. Effect of Route of Administration on the Pharmacokinetic Behavior of Enantiomers of Nefopam and Desmethylnefopam. Ther Drug Mon 2003; 25:203-210.
- Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, Maryanoff BE, and Bialer M. Analysis of Topiramate and Its Metabolites in Plasma and Urine of Healthy Subjects and Patients with Epilepsy by Use of a Novel Liquid Chromatography - Mass Spectrometry Assay. Ther Drug Mon 2003;25:314-322.
- Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WA. K I IV, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 2003; 31 :1043-1048.
- Levy RH, Hachad H, Yao C, Raguneneau-Majlessi I. Relationship Between Extent of Inhibition and Inhibitor Dose: Literature Evaluation Based on the Metabolism and Transport Drug Interaction Database. Curr Drug Metab 2003;4:371-380.
- Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH. Comparison if in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos 2003;31: 565-571. This article received the James R. Gllette Best Paper Award in Metabolism from the American Society for Pharmacology and Experimental Therapeutics.
- Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M. Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide,
and anticonvulsant activity of its metabolites. Epilepsy Res. 2004 Jan;58(1):1-12.
- Levy RH, Ragueneau-Majlessi I, Garnett WR, Schmerler M, Rosenfeld W, Shah J, Pan WJ. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004 Nov;44(11):1230-4.
- Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G, Shah J, Grundy JS. Carbamazepine pharmacokinetics are not affected
by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
- Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of Clinically Significant Pharmacokinetic Interactions Between Zonisamide and Lamotrigine at Steady State in Patients With Epilepsy. Ther Drug Monit. 2005 Apr;27(2):193-198.
- Britzi M, Pecucca E, Soback S, Levy RH, Fattore C, Crema F, Gatti G, Doose DR, Maryanoff BE, Bialer M. Pharmacokinetic and metabolic investigation of Topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia. 2005 Mar;46(3):378-84.
- Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet. 2005;44(5):517-23.
- Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, La Neve A, Soback S, Levy RH, Gatti G, Doose DR, Maryanoff BE, Bialer M. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia. 2005 Jul;46(7):1046-54.
- Perucca F, Berlowitz D, Birnbaum A, Cloyd JC, Garrard J, Hanlon JT, Levy RH, Pugh MJ. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 2006 Jan;68 Suppl 1:S49-63.
- Bialer M, Johannessen SI Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007 Jan;73(1):1-52. Epub 2006 Dec 8.
- Levy RH, Collins C. Risk and predictability of drug interactions in the elderly. Int Rev. Neurobiol. 2007;81:235-51.
- Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Quantitative Correlations Among CYP3A Sensitive Substrates and Inhibitors: Literature Analysis. Current Drug Metabolism, 2007 Dec;8(8):810-4.
|
